The Rasonque pancreatic cancer treatment from Revolution Medicines has received US Food and Drug Administration (FDA) approval for certain patients with metastatic disease. The once-daily oral medicine, also known as daraxonrasib, is approved for patients who have received previous treatment or cannot undergo combination chemotherapy. It targets several forms of the RAS protein, which plays a significant role in driving…